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Abstract
Introduction
Fluoroscopy is currently the standard imaging modality for curettage of atypical cartilaginous
tumors/chondrosarcoma grade 1 (ACT/CS1). Computer-assisted surgery (CAS) is a possi-
ble alternative, offering higher resolution imaging and continuous three-dimensional feed-
back without ionizing radiation use. CAS hypothetically makes curettage more accurate,
thereby decreasing residue or recurrence rate. This study aims to compare CAS and fluo-
roscopy in curettage of ACT/CS1.
Patients and methods
A single center retrospective cohort study was performed. CAS and fluoroscopy were used in
parallel. Included were patients who had curettage for ACT/CS1in the long bones, with a min-
imum follow-up of 24 months. Tumor volume was determined on pre-operative MRI scans.
Outcome comprised local recurrence rates, residue rates, complications and procedure time.
Results
Seventy-seven patients were included, 17 in the CAS cohort, 60 in the fluoroscopy cohort.
Tumor volume was significantly larger in the CAS cohort (p = 0.04). There were no recur-
rences in either group. Residual tumor (2/17 vs. 7/60), complications did not differ signifi-
cantly: fracture rate (3/17 vs. 6/60); nor did surgical time (1.26h vs. 1.34h).
Discussion
CAS curettage showed good oncologic results. Outcome was comparable to fluoroscopy,
while not using ionizing radiation. There was no significant difference in surgical time. Resi-
due rates can likely be decreased with specific software functions and surgical tools.
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Introduction
Atypical cartilaginous tumor/chondrosarcoma grade one (ACT/CS1), ICD-O 9220/1, recently
reclassified from chondrosarcoma grade one (CS-1), is one of the most frequently treated
lesions in orthopedic oncology. [1] The most commonly affected sites are the diametaphysis of
the proximal and distal femur, the proximal tibia and humerus. Incidence of chondrosarcoma
as a whole was estimated in an analysis of the American Surveillance, Epidemiology and End
Results (SEER) database as 1 in 200.000 per year. [2] A report of the European ESMO/EUROB-
ONET registration describes the yearly incidence of chondrosarcoma as ~0.1/ 100.000. [3]
Because of ACT/CS-1’s potentially malignant nature, the surgical goal is a complete removal
of the tumor to prevent local recurrences and its associated decrease in patient survival. [4,5]
Up until around the 1980’s treatment of all chondrosarcoma consisted of resection with a wide
margin. Better clinical and pathological knowledge and improved diagnostic techniques sug-
gested this was not necessary for the less aggressive, low grade, lesions. The current standard
surgical treatment therefore consists of (extended) intralesional curettage generally supported
with fluoroscopy and the use of a local adjuvant such as phenol/ethanol, liquid nitrogen or
argon beam coagulation.[6,7] Reconstruction is done with polymethylmethacrylate (PMMA),
synthetic fillers, allografts or autografts. Depending on location and tumor characteristics, such
as limited X-ray visibility due to cartilages’ lack of mineralization, it can be difficult to perform a
complete curettage. The percentage of residual tumor after curettage is possibly significant,
assuming that (early) local recurrence is often in fact local residue. [8]
Fluoroscopy, the current standard, offers two dimensional imaging and fluoro-video using
X-band radiation. [9] Three-dimensional intra-operative imaging based on MRI may very well be
an improvement in this aspect and there is no intra-operative radiation. With the advances of com-
puter technology in the operating room, a new potential alternative has been developed. Compu-
ter-assisted surgery (CAS) is a relatively new modality, originally developed for neurosurgery in
the early 1990’s. The main advantage of CAS over fluoroscopy is that it gives real-time, continuous,
high resolution 3D feedback, all that and without the use of intra-operative ionizing radiation! It
uses pre-operative computed tomography (CT) and/or magnetic resonance imaging (MRI) scans
as visual datasets. Fusion of both modalities improves image clarity, especially for cartilage contain-
ing tumors. Tracked instruments are visible in the imaging environment. This means the surgeon
is continuously aware of the 3D tumor and instruments location, with feedback on movement in
three dimensions. In theory better orientation through CAS could make the surgery less demand-
ing and improve outcome in recurrence and residue rates. Cited disadvantages for CAS use are
lack of intra-operative assessment of the actual surgical result (i.e. the system shows a virtual result)
and the system takes valuable surgical time to setup and configure. [10,11]
This study aims to compare fluoroscopy and CAS in terms of safety and efficacy in treat-
ment of ACT/CS1 in the long bones.
Patients and methods
Design
A single center retrospective cohort study was performed using the prospectively kept local
bone tumor database. All patients with the procedure code for curettages of bone tumors were
analyzed. In accordance to regulations of the local Medical Ethical Review Board, all patients
were informed about the fact that their data could be used for scientific research. If patients
had objections to the use of their data these data were not included in the study.
CAS vs. fluoroscopy in curettage of ACT/CS1
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Patients
Inclusion criteria were: a curettage type procedure for histologically proven ACT/CS-1 in the
long bones with the use of the adjuvants phenol and ethanol with a minimum follow-up of two
years. Exclusion criteria were: the use of other means of treatment for the same lesion (e.g.
radiofrequency ablation or cryotherapy), a non-complete follow-up and procedures that tre-
ated a recurrence. As this was a retrospective study patients were not randomized. This retro-
spective cohort study does not require an approval of the institutional review board (METc
UMCG), following our research code. Patient approval is registered in the prospectively kept
research database. Both techniques were used in parallel, with CAS use depending on system
availability, planning and dataset quality.
Tumor volume approximation was done for each case on pre-operative MRI scans. The
method used was as described by Verdegaal et al: calculation of the volume of an imaginary
cylinder (π  rmax 2  hmax). For rmax the sum of maximum measured radii anterior-posterior
and medial-lateral was divided by two to produce the maximum radius. We defined hmax as
the largest measurement of proximal-distal size. [8]
Outcome measures
The primary outcome measure was local residue or local recurrence. Local residue was defined
as a suspect lesion (i.e. showing tumor like characteristics) reported on standard post-operative
baseline imaging (MRI 3–6 months post-operative), with consensus between the radiologist
and orthopedic surgeon. When there was no consensus an independent radiologist or ortho-
pedic surgeon was consulted. Recurrence was defined as a positive pathological sample for
ACT/CS-1 after a (radiologically) tumor-free period.
Secondary outcome measures were: complications like fractures, defined as a fracture at the
surgical site regardless of adequate or inadequate trauma, other complications (eg. infection) and
intra-operative and surgical time. Technique related time requirements were compared using the
surgical time and patient-in-OR time. The surgical time was defined as the hours and minutes
between first incision and wound closure as registered in the operative procedures registration
database. Duration of the patient-in-OR time was defined as the period between the registered
times of the patient entered the operating room and patient leaving the operating room.
Patient work-up
Pre-operative workup included a CT scan (for the CAS navigation group), a gadolinium
enhanced MRI with or without Short inversion-Time Inversion Recovery (STIR) fat suppres-
sion sequences. Core needle biopsies were performed to rule out grade 2 chondrosarcoma;
they were done under CT-guidance and classified by one specialized musculoskeletal patholo-
gist (AS) In case of earlier biopsy and referral, the material was revised by the pathologist.
Pathology classification is standardized in the Netherlands by the Dutch Bone Tumor Com-
mittee, following the WHO classifications. [12] Surgical indication were clear diagnosis of
ACT on MRI (e.g. septonodular Gadolinium enhancement, scalloping, wall-to-wall filling,
perilesional oedema), growth of the tumor over time, and/or persistent pain on the tumor site
The procedures were performed by two orthopedic surgeons (JP, PJ).
CAS workflow
The curettages were done without pre-operative planning. Image fusion, generally CT with MRI,
was done in the operating room while the patient was being prepared for surgery. The time con-
sumption of tracker placement and software matching was measured using a stopwatch.
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After bone exposure, the procedure differentiates from a standard (fluoroscopic) procedure
[13]. During a navigated procedure a CAS patient tracker was rigidly attached to the affected
bone using two 3 mm pins. Care was taken not to place the tracker in the expected path of the
curette. Trackers were usually placed at percutaneously near joint lines, for example near the
medial condyle of the femur, the anteromedial tibia plateau or the trochanteric complex. The
pointer tool was then used for position checking, system calibration and remote control of the
software. Image-based navigation was set-up by entering reference points both in the software
and on the patient. The point based match was refined by surface matching where data points
are entered with the pointer tool directly on the navigated bone. The system then presents an
approximation of accuracy based on the difference between the entered points and the bone
surface. The aim was an approximation of accuracy of lower than 1.0 mm. A Stryker Naviga-
tion System II with OrthoMap 3D software (Stryker Mahwah, NJ) was used in all cases. Surface
matching on MRI is not supported on the used system. After the setup of the CAS the place for
the bone window is determined using the pointer tool and the window is made in a regular
fashion. The curettage technique, from a surgical point of view, is not different from a normal
procedure; curettes are used to scrape out the lesion.
The CAS system was used as a continuous-on imaging modality during the curettage pro-
cess. A standard curette was attached to a tracker using a universal clamp and calibrated in the
calibration device (Fig 1). During the procedure the situation on screen did not update as it
was still based on pre-operative imaging data (Fig 2). A final check at the end of the procedure
is performed by using the navigated curette to check the whole cavity: in all directions the
pointer should access beyond the borders of the tumor (Fig 3). Screenshots were taken to regis-
ter the extent of the curettage, comparable to a workflow with fluoroscopy. All CAS procedures
were done without intra-operative fluoroscopy control.
Fluoroscopy workflow
During a fluoroscopy supported curettage procedure imaging data was loaded onto digital dis-
plays in the OR for use during surgery. After dissection the lesion was localized with the fluo-
roscope to guide the place for the bone window. A window was made in a regular fashion in
the cortex of the bone with an osteotome and hammer or electrical saw. The cavity was then
curetted in a systematic clockwise way. Fluoroscopy was used for orientation during the proce-
dure and to check if the curette reaches beyond all the visible edges of the tumor.
In both procedures the second part of the surgery is the same: when the curettage result was
satisfying, the cavity was then partially filled with the first adjuvant: phenol. Small swabs were
used to clean the edges of the whole cavity. The phenol was then washed out with 95% ethanol.
The bone window was also cleaned using this protocol. The cavity was filled with PMMA or
allograft bone chips. When indicated protective osteosynthesis material was applied to prevent a
postoperative fracture (large window size, cortical resorption, diaphyseal localization). Plating
was performed with a tibial LCP plate in diaphyseal lesions with at least two bicortical screws
proximal and distal of the bone window. Weight bearing and return to activities depended on
lesion size and location, usually it was 6 weeks partial weight bearing with crutches.
Follow-up
After surgery, a standard X-ray was obtained as a routine post-operative check. Then a standard
radiograph at the six weeks follow-up and at three to six months a baseline Gadolinium enhanced
MRI. Further controls were yearly done with radiographs till year 3. Then a radiograph at year 5.
When a residue was suspected or if the lesion appeared active, a more frequent MRI follow-up
CAS vs. fluoroscopy in curettage of ACT/CS1
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pattern was chosen. If the osteosynthesis material caused a too large interference for radiological
analysis, even with MRI metal suppression protocols, CT scans were used.
Statistical analyses
Descriptive statistics were used to describe the main characteristics of the patient groups. Gen-
eral patient data as age and sex were compared, depending on data type, using independent
sample t-tests or Pearson chi-square tests. Specific categorical or dichotome variables, as recur-
rence and fracture rates, were compared with Fishers Exact test due to small sample sizes. Dis-
tribution of the different categories of reconstruction methods and the ASA classification were
compared with the Freeman-Halton extension of Fisher’s exact test, using the exact method.
Numerical surgical characteristics data were tested for normality using the Shapiro-Wilk
test and were tested with a Student’s t-test. Non-continuous variables were compared with a
Mann–Whitney U test. To assess potential causes for fractures binary logistic regression tests
were performed with the dichotomous fractures as a dependent variable and calculated lesion
Fig 1. CAS tracker. Instrument tracker attached using a universal clamp to a large curette. Note the maximized three
dimensional spacing of the infrared LED lights. The backside and battery compartment of another instrument tracker
is visible in the background.
https://doi.org/10.1371/journal.pone.0197033.g001
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size variable as continuous predictor and for the fracture rate as dependent variable and
cement use as dichotomous predictor. All tests were done two-sided when applicable. A signif-
icance level of 0.05 was chosen. Analysis of the data was performed with IBM Statistical Pack-
age for the Social Sciences (SPSS) version 22.
Fig 2. CAS procedure. Photograph during a typical CAS supported curettage procedure. Imagebased visualization mode is set to standard view. The system shows the
relevant MRI slices, fused to the CT dataset, based on position of the tool. The ACT/CS1lesion is colored yellow by manual segmentation. The curette is visible as the blue
line and the blue dotted line shows its vector in each direction. The lower right screen shows a volume render of the dataset, with the curette as the blue tool.
https://doi.org/10.1371/journal.pone.0197033.g002
CAS vs. fluoroscopy in curettage of ACT/CS1
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Results
Patient characteristics
Seventy-seven patients were included from 2006 to 2014; 17 patients in the CAS cohort and 60
patients in the fluoroscopy cohort. Mean age at surgery was 53 years (range 24–82 years).
Females were slightly more affected than males with a ratio of 1.1:1. Median follow-up was 79
months (29–134 months, 50–134 for alive patients). Of the 77 patients included for analysis, 75
patients are currently alive; two patients have died of unrelated disease. Further demographic
information is displayed in Table 1 and Fig 4.
Surgical characteristics
Analysis of the pre-operative data showed a significant difference between the lesion width
(medial-lateral), with larger dimensions in the CAS cohort (p = 0.01). Median tumor volume
was 18 cm3. Tumor volume was significantly larger (p = 0.04) in the CAS cohort; 23 cm3 (9
cm3–100 cm3) versus 16 cm3 (1 cm3–61 cm3) (see Table 2).
Fig 3. CAS workflow. Screenshot of the CAS interface during a final check of the curettage. An MRI dataset is used for
navigation in this image. The pointer tool is inserted in the cavity and can extend beyond the tumor boundary.
Annotation point marked by numbers are visible on the most extreme edges of the lesion as a further check.
https://doi.org/10.1371/journal.pone.0197033.g003
Table 1. Demographic characteristics between the two cohorts.
CAS
N = 17
Fluoroscopy
N = 60
p value
Patient age x  years) 56,1 53,8 0.50
Sex >0.99
Male (n, %) 8 (47%) 29 (48%)
Female (n, %) 9 (53%) 31 (52%)
Follow-up xe, months) 77 80 0.52
x  is cohort mean, xe is cohort median.
https://doi.org/10.1371/journal.pone.0197033.t001
CAS vs. fluoroscopy in curettage of ACT/CS1
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Fig 4. General distribution of location of the ACT/CS1 lesions.
https://doi.org/10.1371/journal.pone.0197033.g004
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Patient time in the operating room (patient-in-OR time) (2.15h versus 2.27h) and surgical
time (1.26h versus 1.34h) was lower in the CAS cohort than in the fluoroscopy cohort, however
both differences were not significant. CAS setup was measured in the last ten procedures from
where the procedures deviates from the normal procedure (tracker placement) to the system
fully set-up and running. This took on average 4 minutes and 25 seconds (range 2:03 min to
5:40 min).
Clinical outcome
Nine patients, two in the CAS cohort (2/17, 12%) and seven in the fluoroscopy cohort (7/60,
12%) had a potential residue (p = NS). A more frequent follow-up strategy was initiated for
these cases to check the potential residue for progression. Two of the potential residues have
been biopsied, both in the CAS cohort. Both biopsies showed viable ACT/CS-1 and the resi-
dues were treated using radiofrequency ablation (RFA). There were no recurrences of the
treated tumors in both cohorts (see Table 3).
There were nine fractures, related to the bone window, in the treated patients (9/77, 12%),
all were within five months after the initial surgery and five were within one month. There
were three fractures in the CAS group (3/17, 18%), all three in the diaphysis of respectively the
femur (two) and humerus (one). There were six fractures in the fluoroscopy group (6/60,
10%). Five of these were in the diaphysis of the femur and one in the proximal metaphysic of
the humerus. All were treated with osteosynthesis and are currently healed. The difference in
fracture rate between the CAS and fluoroscopy cohort was not significant. There was no signif-
icant difference in the calculated tumor volume between the groups that had a fracture and
those that did not (median of 19 cm3 versus 14 cm3). Prophylactic plating was done in 14
patients, although this could not prevent a fracture in two cases (12%).
Table 2. Surgical characteristics between the two cohorts.
CAS Fluoroscopy p value
ASA classification 0.92 
ASA I (n, %) 6 (35%) 18 (30%)
ASA II (n, %) 9 (53%) 35 (58%)
ASA III (n, %) 2 (12%) 7 (12%)
Lesion length (xe cm) 6.5 5.2 0.33 
Lesion width (x  cm) 2.5 2.0 0.01 
Lesion depth (x  cm) 2.1 1.9 0.15 
Calculated volume (xe cm3) 23 16 0.04 
Surgical time (xe h:mm) 1:26 1:34 0.29 
OR time (xe h:mm) 2:15 2:27 0.24 
Reconstruction 0.91 
PMMA (n, %) 13 (76%) 45 (75%)
Bonegraft (n, %) 4 (24%) 11 (18%)
Synthetic graft (n, %) 0 3 (5%)
None (n, %) 0 1 (2%)
x  is cohort mean, xe is cohort median. Percentage displayed is percentage of cohort for that specific category.
) Tested using Freeman-Halton extension of Fisher’s exact test.
) tested using Mann–Whitney U test, uniformly for length category.
https://doi.org/10.1371/journal.pone.0197033.t002
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There were eight fractures in the PMMA reconstruction group (8/58, 13.3%), none in the
bonegraft group (0/15 patients, 0%), none in the synthetic bonegrafts group (0/3, 0%) and one
in the no reconstruction group (1/1, 100%). Comparison of the tumor volume between
PMMA and the non-PMMA groups showed no significant difference. The distribution of frac-
tures over the groups was not significant (p = 0.1). In this dataset neither tumor volume, nor
reconstruction method proved to be a predictive value for fractures in binary logistic regres-
sion. No complications were associated with either imaging modality.
Discussion
Computer-assisted surgery has become an accepted treatment modality for difficult tumor
resections.[11,14] While it offers potentially superior imaging feedback there have been no
reports on use of CAS for the curettage of bone tumors, other than a few reported cases for
bone tumors located in the spine. [15] The higher resolution imaging, three-dimensional feed-
back and no limitations in feedback time make CAS a potential alternative to fluoroscopy.
Clinical results of the CAS and fluoroscopy cohorts were comparable, with a significantly
larger tumor volume in the CAS cohort. There were no tumor recurrences according to the
definition; however nine residues were identified (13%). Although these outcome figures seem
satisfying, they are difficult to compare to literature, were recurrence rates are reported
between 3.5% and 13.3%, in studies with similar adjuvants. [16,17]. Important is that this
depends on the interval and modality of follow-up imaging (i.e. MRI vs radiographs).
As Verdegaal et al. have demonstrated, some local recurrences might actually be residues.
[8] ACT/CS-1 is a low grade tumor and generally grows slowly. Thus, suspect lesions on the 3
month baseline scans should be considered tumor residue. In fact all lesions detected within
one year should probably be considered residues. Furthermore studies reporting recurrence
rates using radiographs will likely miss smaller tumor residues. An example of a potentially
missed residue can be seen in an image collage in Fig 5. While the post-operative radiographs
of the knee show no apparent tumor residue the baseline MRI shows a suspect lesion. Taking
this into account, recurrence will likely be over-reported and residue under-reported in studies
using radiographs during follow-up. As residue is primarily a problem of intra-operative ori-
entation, this is something the three-dimensional and high-resolution feedback aspect of CAS
can possibly improve.
Potential residues were found in two out of 17 CAS patients and in seven out of 60 fluoros-
copy patients. Both potential residue cases in the CAS cohorts and one out of the fluoroscopy
cohort showed tumor tissue at biopsy. Actual residue rate for the fluoroscopy cohort may be
lower than six as GD-MRI has positive prediction rate of 45% for actual residue on suspect
Table 3. Clinical outcome.
CAS
N = 17
Fluoroscopy
N = 60
p value
Recurrence (n, %) 0 0 -
(Potential) residue (n, %) 2 (12%) 7 (12%) >0.99
Fractures (n, %) 3 (18%) 6 (10%) 0.41
Other complications (n, %) 0 5 0.58
Clinical outcome between the groups in events and percentage of that category. Complications were split in fractures
and other complications. Other complications are split out in the text.
) Two out of two have positive biopsies and have been treated using RFA.
) No residues have been biopsied or treated.
https://doi.org/10.1371/journal.pone.0197033.t003
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follow-up scans. [8] Analysis of the CAS residue cases did not show a clear cause. Our hypothesis
is that the feedback mode is currently not yet good enough for CAS to be better than fluoroscopy,
especially the lack of progress tracking (i.e. there is no change in the image dataset on screen dur-
ing the procedure). It also shows that it’s not an infallible guide. While no navigational inaccura-
cies were experienced, regular accuracy checks, on a known landmark, are advised during the
procedure to prevent drift.
Fracture rates in this study (12%) are high compared to literature. Recent studies, with the
same adjuvants, show a fracture rate ranging from 5.0 to 6.6 percent. A possible cause for this
can be difference in preventive osteosynthesis strategies. [7,17–21] 58 of the 77 patients treated
in this study had a reconstruction with PMMA. While it is suspected that the exothermic
PMMA hardening process can have a beneficial effect as an adjuvant, it may have an negative
effect on the host bone. Literature shows no significant difference in recurrence and fracture
rates between using PMMA or other reconstruction methods. [17,22] As there were no recur-
rences, we cannot draw conclusions on PMMA and recurrence rate. Fracture rate in PMMA
seems higher with 8 fractures out of 58 patient treated (14%) compared with a 6% fracture rate
in the other reconstruction methods, although this did not reach significance. As the fracture
rate was considered too high, a more aggressive plating strategy (longer plates and more cortices
for smaller lesions) was adopted for procedures in the diaphysis of the femur. There was also a
possible bias in fracture risk as a concurrent radiofrequency ablation (RFA) trial meant the
exclusion of patients with mainly smaller ACT/CS-1 lesions in the femoral metaphysis. [23]
The often cited downside of CAS use, the long set-up time, was not experienced. [10] Set-
up time, measured in the later cases, was on average just 4 minutes and 25 seconds. This was
with an experienced team with over 50 procedures into the learning curve. The median surgi-
cal and patient in OR time was less than for fluoroscopy. While not significantly better, it
shows that the set-up time is recouped during the procedure.
Use of CAS has been described by both surgeons as useful, due to the continuous three
dimensional feedback, compared with the intermitted two dimensional feedback in fluoros-
copy. It was helpful in checking for complete removal in difficult zones for example directly
around the cortical window. Application of CAS in the humerus was considered more difficult
due to issues with tracker placement in the working field. Smaller trackers could solve this
Fig 5. Residue. Series of images of a female patient after a CAS procedure for CHS1 in the right distal femur. A: the
post-operative radiograph (Follow-up: 0 days). The defect is reconstructed with a bonechips (bonegraft). No residue
visible. B: shows the baseline MRI scan of the same patient (follow-up 3 months). The depicted TIRM sequence shows
a reactive response to the graft, with local edema. However below the reconstruction is another lobular, fluid rich
structure: retrospectively suggestive forlocal residue but the radiologist describes it as most likely a postoperative
reaction of the bone. Further radiographic follow-up shows no recurrence. C: TIRM sequence of the same patient
(follow-up: 25 months) shows a nearly died down reaction to the graft but a comparable reaction in the suspected
zone. Biopsy before RFA treatment confirmed CHS-1 tissue.
https://doi.org/10.1371/journal.pone.0197033.g005
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issue. There were no direct complications nor any morbidity related to use of the CAS system.
Possible complications as pin tract fractures or pin tract infections did not occur.
Inter-observer variability is a high and ongoing issue in the grading of cartilaginous bone
tumors. The SLICED study group reported that grading reliability, even by experienced
pathologists and radiologist, is low and that this may partially explain difference in outcomes
between centers [24]. The difference is even highest between discerning enchondroma and
low grade chondrosarcoma (kappa 0.54) [25]. In this study one specialized pathologist with
extensive expertise in sarcoma and two specialized radiologist either reviewed the samples or
supervised a resident for nearly all the cases. All external work was reviewed. Guidelines on
classification for ACT/CS1 were rigidly followed.
This study has some limitations. It was set-up as a retrospective cohort study, the study pop-
ulation was not equally divided and the techniques were not actively randomized. Both the tech-
niques were however used in parallel, with CAS use only depending on system availability,
planning and dataset quality. The only adjuvant treatment in this study was phenol/ethanol,
results may be different using argon beam coagulation or cryotherapy as adjuvant. CAS curet-
tage was tested only for ACT/CS1, the effect on lesions with higher recurrence rates as giant cell
tumor may be different. As far as we know, this is the first study on the usage of CAS for curet-
tage of ACT/CS-1 in the long bones. This study can be seen as a pilot study on CAS efficacy.
Some improvements to workflow and instruments will probably have a positive effect on
outcome measurements. Currently it’s not possible to see the extent of the already treated area.
A ‘paintbrush’ mode, where the position of the tip is painted into the three-dimensional view
would provide feedback on surgical progress. This together with the addition of a planning
mode to the software could provide an intra-operative residue check (i.e. coloring in the
planned 3d structure). Furthermore it is likely that a more accurate curettage with less healthy
bone removed can decrease fracture rates. Also, there should be support for non-straight tools
like bended, hockey stick, shaped curettes and pointers, for easier access to tumor tissue in cor-
ners of the lesion.
Conclusion
CAS curettage with phenol/ethanol adjuvants has shown good oncological results at medium
length follow-up, at least comparable to the fluoroscopy cohort and literature. CAS curettage
in this study was safe and effective. There were no recurrences, and no difference in the occur-
rence of residues between the cohorts, this despite significantly larger lesions in the CAS
cohort. Fracture rates in both groups were higher than expected. In this study this was not
linked to CAS technique, PMMA use or size of the lesions.
Especially a suspected high residue rate after curettage supports the development of better
intra-operative orientation. Clinical outcome of the present study supports CAS use as an
alternative to fluoroscopy. With CAS no ionizing radiation was used during these surgeries
and there was no increase in surgical time. Residue rates can likely be improved with specific,
curettage targeted, software modules and tools.
-
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